Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.42 |
| ▸ | CA2 | P00918 | 13/20 | 0.42 |
| ▸ | CA7 | P43166 | 11/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 11/20 | 0.42 |
| ▸ | CA12 | O43570 | 9/20 | 0.42 |
| ▸ | CA9 | Q16790 | 8/20 | 0.42 |
| ▸ | CA6 | P23280 | 6/20 | 0.42 |
| ▸ | CA3 | P07451 | 5/20 | 0.42 |
| ▸ | CA4 | P22748 | 5/20 | 0.42 |
| ▸ | CA5A | P35218 | 5/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956735 | 0.90 | ESR1 (0.36) | CA1CA2CA7CA13CA12 | |
| SCHEMBL3955598 | 0.86 | BRD4 (0.35) | ESR1ESR2CNR2MEN1KMT2A | |
| SCHEMBL3950716 | 0.85 | DCTPP1 (0.40) | ESR1ESR2MEN1KMT2A | |
| SCHEMBL3949489 | 0.80 | KMT2A (0.38) | ESR1ESR2MEN1KMT2A | |
| SCHEMBL27582861 | 0.80 | ESR1 (0.35) | ESR1ESR2MEN1KMT2A | |
| SCHEMBL1625626 | 0.80 | CNR2 (0.35) | CA1CA2CA7CA13CA12 | |
| SCHEMBL3950874 | 0.79 | ESR1 (0.37) | ESR1ESR2MEN1KMT2A | |
| SCHEMBL1625975 | 0.78 | CNR2 (0.35) | CA1CA2CA7CA13CA12 | |
| SCHEMBL3949979 | 0.78 | CNR2 (0.36) | ESR1ESR2CNR2MEN1KMT2A | |
| SCHEMBL5777836 | 0.78 | PGK1 (0.40) | ESR1ESR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100579518-C | Use of EP4 receptor ligands for the manufacture of a medicament for the treatment of IL-6 related disorders | PFIZER | 2010-01-13 | — | — | CN | disclosed |
| US-7479564-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC. (JP) | 2009-01-20 | — | — | US | disclosed |
| CN-101023946-A | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER (US) | 2007-08-29 | — | — | CN | disclosed |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PFIZER INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PFIZER INC. | 2007-03-22 | — | — | US | disclosed |
| US-7141580-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1666480-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. | PFIZER PHARMACEUTICALS INC. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1326864-B1 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMA (JP) | 2006-03-15 | — | — | EP | disclosed |
| CN-1658847-A | Use of EP4 receptor ligands for the treatment of IL-6 related disorders | PFIZER (US) | 2005-08-24 | — | — | CN | disclosed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| CN-1477960-A | EPA receptor inhibitors to treat rheumatoid arthritis | — | 2004-02-25 | — | — | CN | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | CA1 2229/4885CA2 343/4885CA7 1455/4885 |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PTGER4, PTGER1, IL6 | CA1 4549/4885CA2 4405/4885CA7 4498/4885 |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | CA1 2298/4885CA2 364/4885CA7 1459/4885 |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PTGS1, PTGS2, PTGES | CA1 3016/4885CA2 711/4885CA7 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.